Press Releases - Tear Solutions

Press Releases

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep^® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. Secures $3M Series B Funding

TearSolutions, Inc., Announces Results From First-In-Human Clinical Trial published in Cornea

TearSolutions, Inc. Appoints Leonard Borrmann To Its Board of Directors

TearSolutions, Inc. Announces Results from Phase I/II trial of Lacripep TM to Treat Primary Sjögren’s Syndrome and Appoints Anil Asrani President and CEO

Middleland Capital’s VTC Innovation Fund and Pharmstandard International Co-lead $8.5m Series B Financing of TearSolutions, Inc.

TearSolutions Raises $3M Series A Round to Advance The Treatment of Dry Eye

TearSolutions, Inc. Appoints Leonard Borrmann To Its Board of Directors

Middleland Capital’s VTC Innovation Fund and Pharmstandard International Co-lead $8.5m Series B Financing of TearSolutions, Inc.

TearSolutions, Inc. Announces Results from Phase I/II trial of Lacripep TM to Treat Primary Sjögren’s Syndrome and Appoints Anil Asrani President and CEO

TearSolutions Raises $3M Series A Round to Advance The Treatment of Dry Eye

TearSolutions, Inc., Announces Results From First-In-Human Clinical Trial published in Cornea

TearSolutions, Inc. Announces Results From First In Human Clinical Trial published in Cornea

TearSolutions, Inc., Announces Results From First-In-Human Clinical Trial published in Cornea

TearSolutions, Inc. Appoints Leonard Borrmann To Its Board of Directors